TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05003986: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Sponsor: Travere Therapeutics, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT05003986 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05003986 Rescue Dossier →